Are you over 18 and want to see adult content?
More Annotations
A complete backup of wirtschaftszeit.at
Are you over 18 and want to see adult content?
A complete backup of cherishedbliss.com
Are you over 18 and want to see adult content?
A complete backup of energimyndigheten.se
Are you over 18 and want to see adult content?
A complete backup of xn----7sbbaigi3a9bffsher.xn--p1ai
Are you over 18 and want to see adult content?
A complete backup of cbdoilsforsales.com
Are you over 18 and want to see adult content?
A complete backup of ihatecarmaxscion.com
Are you over 18 and want to see adult content?
A complete backup of voyagespourlaplanete.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of autolaborexpert.com
Are you over 18 and want to see adult content?
A complete backup of estellesinclair.com
Are you over 18 and want to see adult content?
A complete backup of humanesources.com
Are you over 18 and want to see adult content?
A complete backup of estructurando.net
Are you over 18 and want to see adult content?
A complete backup of lottonumbers.com
Are you over 18 and want to see adult content?
Text
Search
Investors
News & Media
Careers
Contact
Follow Us
* About
* About
* Our Mission & Values* Leadership
* Board of Directors * Corporate Citizenship* Charitable Grants
* Compliance
* Open Payments FAQs* Products
* Products
* ADCETRIS® (brentuximab vedotin) - US * PADCEV™ (enfortumab vedotin-ejfv) – U.S. * TUKYSA™ (tucatinib) * Science & Innovation * Science & Innovation* ADC Technology
* ADC Collaborations* Pipeline
* Pipeline
* Brentuximab Vedotin * Enfortumab Vedotin* Tisotumab Vedotin
* Tucatinib
* Ladiratuzumab Vedotin * Patients & Healthcare Professionals * Patients & Healthcare Professionals* Clinical Trials
* Trial Information for Patients * Participating in a Clinical Trial * Medical Information * Global Medical Information * Europe Medical Information and Product Safety * Investigator-Sponsored Trials * Clinical Data Requests * Independent Medical EducationSearch
Investors
News & Media
Careers
Contact
Follow Us
REVOLUTIONARY SCIENCE MEETS TRANSFORMATIVE CANCER THERAPY Mike, treated for classical Hodgkin LymphomaHIGHLIGHTS
Download
Our COVID-19 Business UpdateGet update
First Quarter 2020 Financial Results - April 30, 4:30pm ETLISTEN TO WEBCAST
RECENT NEWS
SEATTLE GENETICS ANNOUNCES THE APPROVAL OF TUKYSAâ„¢ (TUCATINIB) IN SWITZERLAND FOR THE TREATMENT OF PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER MORE SEATTLE GENETICS TO PRESENT AT THE BOFA SECURITIES VIRTUAL HEALTH CARE CONFERENCE 2020 MOREMORE
View All News
*
Despite the #COVID19 pandemic, people living with metastatic #breastcancerlike
@christeeny513 rely on research and… twitter.com/i/web/status/1…·Â 1 day ago
*
Feelings of isolation and fear are not unusual for those living with metastatic #breastcancer. @christeeny513
share…
twitter.com/i/web/status/1…·Â 1 week ago
FROM PROMISE TO THERAPY Seattle Genetics is conducting clinical trials in these and othertherapeutic areas:
* Hodgkin lymphoma
* Non-Hodgkin lymphoma* Urothelial cancer
* Breast cancer
View all clinical trials JOIN THE SEATTLE GENETICS TEAM We are a growing, mission-driven company with a culture built for passionate team players wanting to make a difference.Learn More
SEATTLE GENETICS AT A GLANCESize
Largest biotech in the Pacific NorthwestGlobal Headquarters
Bothell, WA
European Office
Zug, Switzerland
Number of Employees
1,800+
Public Company
Nasdaq:SGEN
©2020 Seattle Genetics, Inc. Contact Us | Privacy Policy| Legal Notices
×
LEAVING SEATTLE GENETICS You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com? Close Yes, leave SeattleGenetics.comDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0